Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Paraffin hard
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · Randomised trials: 1 · 1974–2026
Showing the 50 most relevant studies, sorted by most relevant.
Heselich A, Najafi R, Alammawi S, et al.
2026
Alveolar ridge preservation using biomaterials is a well-established approach to counteract post-extraction bone resorption and optimize conditions for implant placement. However, most studies rely only on a single evaluation method and thereby risk overlooking essential aspects of alveolar regeneration. This preliminary analysis aimed to assess alveolar ridge preservation outcome using a multimodal approach combining histomorphometric, radiological, and image-based visualization methods. Twenty out of a planned 60 patients per group from an ongoing randomized controlled clinical trial were included. Patients were allocated to alveolar ridge preservation with a bone substitute material (BSM), a collagen-based material, a combination of both, or natural healing as control. Outcomes included CBCT-based volumetric analysis, histomorphometry, and primary implant stability via ISQ. Mineralized bone volume was significantly better preserved in bone substitute material groups compared to other groups, with BSM combined with collagen yielding the highest values. Histomorphometrically determined hard tissue fractions and implant stability were comparable across groups. Notably, CBCT-based visualization revealed non-ossified hypodense regions, so-called cavitations or covered socket residuum (CSR) within the former extraction sockets across all groups, independent of the biomaterial applied. BSM-based alveolar ridge preservation, particularly combined with a collagen membrane, most effectively maintained mineralized bone volume after extraction. Beside volumetric benefits, this preliminary in-dept analysis of the first part of the trial highlights cavitations/CSRs as a potentially underrecognized feature of post-extraction healing. Integrating quantitative with qualitative visualization-based assessments provides a more complete understanding of alveolar bone regeneration.
Abstract licence: CC BY
J Musil, F Kunc, H Zeman, et al.
Surface and Coatings Technology, 2002
Paolo Raggi, Bruce Cooil, Tracy Q. Callister
American Heart Journal, 2001
I. Krupa, G. Miková, A. S. Luyt
European Polymer Journal, 2007
B.A Cook, J.L Harringa, T.L Lewis, et al.
Scripta Materialia, 2000
S. Carlquist
Stain technology, 1982
Streinu DR, Bena A, Icma I, et al.
2026
Background: Riedel's thyroiditis is a rare fibrosing thyroid disorder that remains one of the most difficult to diagnose, often being initially interpreted as malignant due to its clinical, radiological, and histopathological similarities with anaplastic carcinoma or other infiltrative thyroid diseases. Preoperative investigations, including fine-needle aspiration cytology (FNAC), may be misleading and contribute to an erroneous diagnosis of cancer. Methods: We report the case of a 44-year-old woman presenting with a rapidly enlarging, hard goiter associated with compressive symptoms and cytological findings suspicious for papillary thyroid carcinoma (Bethesda V). Based on these findings and the multidisciplinary team's assessment, surgical intervention was undertaken. Intraoperatively, the thyroid gland was densely fibrotic and adherent to adjacent structures, prompting frozen-section analysis that revealed a benign fibroinflammatory process consistent with Riedel's thyroiditis. This intraoperative finding guided the surgical team toward a near-total thyroidectomy, preventing unnecessary radical excision. Results: The paraffin-embedded section confirmed the diagnosis. Postoperative recovery was favorable, with complete resolution of compressive symptoms. Conclusions: This case highlights the persistent diagnostic challenges of Riedel's thyroiditis and illustrates how intraoperative frozen-section examination can contribute to differentiating it from malignancy when preoperative findings remain inconclusive. A multidisciplinary approach and surgical expertise are essential in tailoring the extent of resection, preventing complications, and achieving both diagnostic confirmation and symptom relief.
Abstract licence: CC BY
T. Boublík, I. Nezbeda
Chemical Physics Letters, 1977
P.H Mayrhofer, H Willmann, C Mitterer
Surface and Coatings Technology, 2001
S. Berger, R. Porat, R. Rosen
Progress in Materials Science, 1997
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.